Detalhe da pesquisa
1.
Predicting clinically significant prostate cancer following suspicious mpMRI: analyses from a high-volume center.
World J Urol
; 42(1): 290, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702557
2.
The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis.
Eur J Nucl Med Mol Imaging
; 50(1): 218-227, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35984452
3.
ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.
Future Oncol
; 16(2): 4359-4368, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31823654
4.
STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy.
Int J Mol Sci
; 21(3)2020 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32046095
5.
Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.
World J Urol
; 36(2): 177-185, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29164326
6.
Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
J Urol
; 197(1): 143-148, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27418452
7.
No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy.
J Urol
; 195(2): 343-8, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26239337
8.
CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1.
J Urol
; 195(3): 771-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26318986
9.
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 16(4): 417-25, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25743937
10.
11C-Choline PET/pathology image coregistration in primary localized prostate cancer.
Eur J Nucl Med Mol Imaging
; 41(12): 2242-8, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25186430
11.
Prevalence of bilateral loco-regional spread in unilateral pelvic PSMA PET positive recurrent prostate cancer.
Minerva Urol Nephrol
; 75(6): 734-742, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38126286
12.
Gender and body mass index as risk factors for bladder perforation during primary transurethral resection of bladder tumors.
J Urol
; 187(5): 1566-70, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22425072
13.
Ileal neobladder in women with bladder cancer: cancer control and functional aspects.
Curr Opin Urol
; 21(6): 478-82, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21897260
14.
Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer.
J Exp Clin Cancer Res
; 38(1): 322, 2019 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31331377
15.
5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer.
Clin Cancer Res
; 13(7): 2136-43, 2007 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17404097
16.
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
PLoS One
; 13(1): e0190854, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29357370
17.
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Hum Pathol
; 38(5): 696-701, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17320151
18.
Tissue engineered venous matrices for potential applications in the urogenital tract.
Tissue Eng
; 13(10): 2475-82, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17638519
19.
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
JAMA Oncol
; 3(1): 68-75, 2017 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27560549
20.
Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity.
Oncogene
; 24(48): 7190-202, 2005 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-16091752